Investor Presentaiton
DELORAINE ACQUISITION
A critical acquisition supporting our vertical integration vision. Deloraine is purpose built
with advanced infrastructure and capacity to process 10 million tins per annum.
For personal use only
21
22
bübs
Key Highlights
bübs
1 of only 15 CNCA accredited infant formula facilities
in Australia.
Deloraine carries SAMR brand nominations for both
BubsⓇ Goat Infant Formula and Bubs Organic® Infant
Formula, required for direct
export to China - pending registration approval.
The acquisition was enabled via a share placement to
C2 Capital Partners, who now has an aggregate 15%
holding in Bubs Australia.
Alibaba Group is an anchor investor in C2 Capital
Partners (C2). This profoundly valued partnership
provides Bubs with unique China market insights and
know-how. Consequently, C2's Managing Partner,
Steve Lin has joined Bubs Board.View entire presentation